XTX Topco Ltd Invests $276,000 in Silk Road Medical, Inc (NASDAQ:SILK)

XTX Topco Ltd bought a new position in shares of Silk Road Medical, Inc (NASDAQ:SILK) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 10,191 shares of the company’s stock, valued at approximately $276,000.

Other institutional investors also recently modified their holdings of the company. PNC Financial Services Group Inc. grew its position in shares of Silk Road Medical by 1,293.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,523 shares of the company’s stock worth $31,000 after buying an additional 2,342 shares during the period. Quest Partners LLC acquired a new position in shares of Silk Road Medical in the 4th quarter valued at approximately $62,000. SG Americas Securities LLC acquired a new position in shares of Silk Road Medical in the 1st quarter valued at approximately $109,000. Rathbones Group PLC acquired a new position in shares of Silk Road Medical in the 2nd quarter valued at approximately $201,000. Finally, State Board of Administration of Florida Retirement System grew its position in shares of Silk Road Medical by 9.9% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 12,065 shares of the company’s stock valued at $221,000 after purchasing an additional 1,090 shares during the period.

Insider Transactions at Silk Road Medical

In related news, EVP Kevin M. Klemz sold 2,268 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $27.10, for a total value of $61,462.80. Following the sale, the executive vice president now owns 162,926 shares in the company, valued at approximately $4,415,294.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 3.90% of the company’s stock.

Silk Road Medical Trading Down 0.0 %

Shares of Silk Road Medical stock opened at $27.49 on Friday. Silk Road Medical, Inc has a 12-month low of $6.08 and a 12-month high of $27.51. The stock has a market cap of $1.12 billion, a P/E ratio of -20.07 and a beta of 1.53. The company has a quick ratio of 6.69, a current ratio of 7.63 and a debt-to-equity ratio of 0.49. The business’s 50 day moving average is $27.17 and its 200-day moving average is $23.33.

Silk Road Medical (NASDAQ:SILK) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04). Silk Road Medical had a negative return on equity of 37.30% and a negative net margin of 29.53%. The company had revenue of $51.20 million for the quarter, compared to the consensus estimate of $49.74 million. During the same quarter in the prior year, the company earned ($0.35) EPS. The company’s revenue for the quarter was up 13.0% on a year-over-year basis. Equities research analysts predict that Silk Road Medical, Inc will post -1.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SILK has been the subject of several research analyst reports. Stifel Nicolaus reiterated a “hold” rating and issued a $27.50 price objective (up from $23.00) on shares of Silk Road Medical in a research report on Wednesday, July 17th. Lake Street Capital reiterated a “hold” rating and issued a $27.50 price objective (down from $28.00) on shares of Silk Road Medical in a research report on Tuesday, June 18th. Finally, Argus lowered Silk Road Medical from a “buy” rating to a “sell” rating in a research report on Thursday, July 11th. Two investment analysts have rated the stock with a sell rating and seven have assigned a hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $20.29.

Silk Road Medical Company Profile

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.